BridgeBio Pharma BBIO Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's accrued expenses?
- BridgeBio Pharma (BBIO) reported accrued expenses of $39.34M in Q1 2026.
- How has BridgeBio Pharma's accrued expenses changed year-over-year?
- BridgeBio Pharma's accrued expenses increased by 17.6% year-over-year, from $33.45M to $39.34M.
- What is the long-term trend for BridgeBio Pharma's accrued expenses?
- Over 5 years (2020 to 2025), BridgeBio Pharma's accrued expenses has grown at a 20.9% compound annual growth rate (CAGR), from $29.68M to $76.7M.
- What does accrued expenses mean?
- Expenses that have been incurred but for which no invoice has been received or payment made yet.
- How do you interpret accrued expenses?
- Rising accruals often reflect increasing operational activity or the timing of periodic service contracts.
- How does accrued expenses compare across companies?
- Accrued expenses are standard across the industry and fluctuate based on the timing of corporate cycles and clinical trial milestones.